5 hours ago
1
- The U.S. FDA has issued a Complete Response Letter to Ultragenyx Pharmaceutical (NASDAQ:RARE) for its BLA for UX111 (ABO-102), its AAV gene therapy to treat Sanfilippo syndrome type A.
- The company said that the agency cited issues related to chemistry, manufacturing
English (US) ·